A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice

Recruiting now

Conditions studied: Psoriasis

In brief

The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.

Key facts

Study ID

NCT07746583

Run by

Janssen-Cilag Kft.

People needed

100

Starts

2026-08-07

Expected to finish

2029-02-07

Last updated by the study team

2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
• Participants who are currently being treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab, or for whom this switch is medically indicated, based on the current and valid national psoriasis (PsO) therapeutic protocol
• Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab
• Participants must sign an informed consent form (ICF) allowing for data collection and source data verification in accordance with local requirements

You may not qualify if…

• Contraindication or hypersensitivity to Guselkumab or any other ingredient in the injection solution
• Pregnancy or breastfeeding
• Currently enrolled in an interventional study
• Currently enrolled in an observational study sponsored or managed by a Janssen company
• Previous use of guselkumab in any indication in participant history

Where it is running

• Semmelweis University — Budapest, Hungary (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.